Ratings UMediC Group

Equities

UMC

MYQ0256OO006

End-of-day quote BURSA MALAYSIA Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
0.685 ^MYR	-1.44%		-4.20%	-2.84%

12/03	UMediC Group's Profit Slips in Fiscal Q2; Shares Rise 3%	MT
11/03	UMediC Group Berhad Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

With an enterprise value anticipated at 4.17 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
UMEDIC GROUP	-2.84%	54.83M	-
ABBOTT LABORATORIES	-4.85%	182B	C+
MEDTRONIC PLC	+1.68%	110B	C
BECTON, DICKINSON AND COMPANY	-2.89%	68.11B	A
DEXCOM, INC.	+1.06%	50.53B	B-
CENCORA, INC.	+8.84%	44.8B	B-
HOYA CORPORATION	+2.84%	40.7B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+19.67%	32.25B	B
WEST PHARMACEUTICAL SERVICES, INC.	+2.17%	26.53B	A-
TERUMO CORPORATION	+15.25%	25.02B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes